Skip to main content

Less Frequent, Higher Dose Kyprolis Improves Progression-Free Survival

November 20, 2017

Recent research from the phase 3 ARROW trial showed that higher-dose, once weekly Kyprolis (carfilzomib; Amgen) improved progress-free survival in patients with patients with relapsed/refractory multiple myeloma, according to a results released by Amgen.

ARROW is a randomized, open-label, phase 3 clinical trial of patients receiving Kyprolis in combination with Dezamethasone. The trial took place at about 100 care sites throughout the world.

The researchers studied 478 patients with relapsed and refractory multiple myeloma who already received two or three treatment lines. In order to determine the efficacy of a once-daily regimen, they sorted the cohort into two study groups, a group that received a higher-dose (70 mg/m2) of Kyprolis once per week, and a group that received two lower doses (27 mg/m2) twice per week. The researchers measure progression-free survival as the primary outcome and overall response rate, overall survival, and safety and tolerability as secondary endpoints.

“Kyprolis has been demonstrated to be the most effective proteosome inhibitor available to patients with multiple myeloma,” Sean E Harper, M.D., executive vice president of Research and Development at Amgen, said in the press release. “We are encouraged by the efficacy and safety profile of KYPROLIS and dexamethasone administered once-weekly in the ARROW study.”

Study results showed that patients in the once-weekly group had significantly greater progression free survival, at 3.6 longer than patients in the twice-weekly group (11.2 months vs 7.6 months).

The researchers noted that the most common treatment-emergent adverse events were anemia, diarrhea, fatigue, hypertension, insomnia, and pyrexia in both study groups.

David Costill

For more articles like this, visit the Health Care News Resource Center

For articles by First Report Managed Care, click here

To view the First Report Managed Care print issue, click here

Back to Top